Navigation Links
Many Ovarian Cancer Patients Denied By-the-Book Care, Study Says
Date:3/12/2013

By Kathleen Doheny
HealthDay Reporter

MONDAY, March 11 (HealthDay News) -- Nearly two-thirds of ovarian cancer patients don't receive recommended treatment that could extend their lives, U.S. researchers have found.

For patients who didn't get care that follows the National Comprehensive Cancer Network (NCCN) clinical practice guidelines, the risk of dying within five years of follow-up was 30 percent greater compared to women who got recommended treatment, said researcher Dr. Robert Bristow, director of gynecologic oncology at the School of Medicine of the University of California, Irvine.

Low-volume hospitals -- those that treat few cases of ovarian cancer -- are less likely than larger hospitals to follow the established recommendations for ovarian cancer, according to the study.

The findings lend support to the guidelines, Bristow said.

Women facing treatment for ovarian cancer, he said, should ask their doctor: "How many ovarian cancer patients do you treat a year?" If the answer is two, "You probably don't want to be one of those patients," Bristow said.

Each year, about 22,000 new cases of ovarian cancer are diagnosed in the United States, and more than 15,000 women die of it, according to the American Cancer Society.

For the study, Bristow and his colleagues analyzed the treatment and results for more than 13,000 women with ovarian cancer, using data reported to the California Cancer Registry from 1999 through 2006.

That time period was selected because there was no overall change in treatment approaches during those years, Bristow said. Such changes might have affected the results, scheduled for presentation Monday at the Society of Gynecologic Oncology annual meeting in Los Angeles.

Half the women studied were younger than 61, and the majority, 70 percent, had advanced cancer. First, the researchers looked to see how many women got treatment as recommended by the cancer network. The network is an alliance of 21 cancer centers that develops treatment guidelines.

Only 4,952, or 37 percent, got the recommended treatment.

Bristow's team looked at patient-related and health care system factors that might predict better adherence to treatment guidelines. They found the number of cases of ovarian cancer treated by the hospital and by individual doctors played a role.

"The high-volume hospitals, which did 20 or more cases a year, and high-volume physicians, which did 10 or more a year, were significantly more likely to administer treatment that was adherent to NCCN guidelines," Bristow said.

But even high-volume hospitals weren't always in compliance with the guidelines. High-volume hospitals delivered appropriate care 51 percent of the time, compared to 34 percent by low-volume facilities. High-volume doctors delivered appropriate care 48 percent of the time, compared to 34 percent by low-volume doctors.

Most of the women got care at low-volume facilities by doctors with little experience treating ovarian cancer.

Treatments include surgery and chemotherapy. In many cases, doctors provided some of the recommended care -- either chemo or surgery -- but not both, Bristow found.

In some cases, Bristow said, it's not possible to follow guidelines. For instance, an elderly women with other health issues, such as congestive heart failure, probably couldn't tolerate chemotherapy, he said.

A California-based expert, Dr. Mark Wakabayashi, said the finding ''echoes previous findings and my own clinical practice." Wakabayashi, division chief of gynecologic oncology at the City of Hope Comprehensive Cancer Center, said he has treated many women whose previous cancer care did not follow these guidelines.

Compared to the national norms, survival statistics at high-volume centers are higher, he said.

But many women don't have access to a high-volume center. In those cases, he suggested they ask their doctor: "Do you follow NCCN guidelines?"

Data and conclusions presented at medical meetings are typically considered preliminary until published in a peer-reviewed medical journal.

More information

For more on the national guidelines for cancer treatment, visit the National Comprehensive Cancer Network.

SOURCES: Robert Bristow, M.D., professor and director, gynecologic oncology, University of California - Irvine School of Medicine; Mark Wakabayashi, M.D., chief of gynecology oncology, City of Hope Comprehensive Cancer Center, Duarte, Calif.; Society of Gynecologic Oncology annual meeting, March 11, 2013, Los Angeles


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Abdominal Chemo Bath May Extend Survival in Ovarian Cancer Patients
2. Scientists uncover source of ovarian stem-like cells prone to give rise to ovarian cancer
3. Origin of aggressive ovarian cancer discovered
4. Gene Mutations Benefit for Ovarian Cancer Patients May Not Last: Study
5. Researchers discover breakthrough in ovarian cancer
6. Deep genomic analysis identifies a micro RNA opponent for ovarian cancer
7. Study drug is first to help patients with recurrent low-grade ovarian cancer
8. 2-step immunotherapy attacks advanced ovarian cancer
9. Preclinical study identifies master proto-oncogene that regulates ovarian cancer metastasis
10. Study shows high blood calcium levels may indicate ovarian cancer
11. Developed new method to diagnose hereditary breast and ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is ... natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO ... to create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... ... December 05, 2016 , ... The ... care facility – Avamere Transitional Care of Puget Sound ; located at ... health care center will provide patients recovering from illness or injury with intensive ...
(Date:12/5/2016)... VA (PRWEB) , ... December 05, 2016 , ... ... today announced it has been featured in SuperbCrew magazine, a leading online tech ... tech world. This interview, now featured on SuperbCrew.com, explores the state of enterprise ...
(Date:12/5/2016)... ... ... Researchers at Johns Hopkins All Children’s Hospital want to learn more about ... of three years, researchers will study concussions and changes in brain function by monitoring ... sensors, will track the location and force of the hit. The sensors store data ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy ... through tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on the ... 26 people will be diagnosed with epilepsy within their lifetime. With such a ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Spain Glaucoma Surgery Devices Market Outlook to ... Surgery Devices Market Outlook to 2022", provides key market ... report provides value, in millions of US dollars, volume ... - Canaloplasty Micro Catheters and Glaucoma Drainage Devices. ... data for each of these market segements, and global ...
(Date:12/5/2016)... -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ), the ... and manufacturing data that support SB-525, its gene therapy program ... of the American Society of Hematology (ASH) being held in ... 2016. "We have developed an improved gene therapy ... highly competitive, and we remain on track to file an ...
(Date:12/5/2016)... Dec. 5, 2016  Cornerstone Pharmaceuticals, Inc., a ... data from two Phase I trials evaluating its ... 58th annual meeting of the American Society of ... . The two datasets show encouraging efficacy ... leukemia (AML) and T-cell non-Hodgkin,s lymphoma (T-cell NHL), ...
Breaking Medicine Technology: